Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03862131 · ClinicalTrials.gov registry record · Phase 2
PROactive Evaluation of Function to Avoid CardioToxicity
A Phase 2 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
NCT03862131 is a Phase 2 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 49 participants.
The verdict
NCT03862131, a Phase 2 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
Study Summary
This study is intended to evaluate the ability of an intramyocardial strain analysis package with cardiac MRI to assist in the early detection and management of cardiotoxicity from therapeutics used to treat cancer.
Interventions
- DEVICE MyoStrain®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2019-03-13 |
| Est. Completion | 2024-06-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03862131
The ClinicalTrials.gov registry entry for NCT03862131 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MyoStrain® is the first listed.
NCT03862131 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03862131 about?
NCT03862131 is a clinical study titled "PROactive Evaluation of Function to Avoid CardioToxicity". This study is intended to evaluate the ability of an intramyocardial strain analysis package with cardiac MRI to assist in the early detection and management of cardiotoxicity from therapeutics used to treat cancer.
What is the current status of trial NCT03862131?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2019-03-13. Estimated completion is 2024-06-14.
What interventions are being tested in trial NCT03862131?
The interventions under investigation include: MyoStrain® (DEVICE).
Who is sponsoring clinical trial NCT03862131?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.